| ［1］ |
Silva HA，Raimundo D，Dias MF，et al.Molecular detection of EGFRvⅢ-positive cells in the peripheral blood of breast cancer patients［J］.Eur J Cancer，2006，42（15）：2617-2622.
|
| ［2］ |
Yu H，Gong X，Luo X，et al.Co-expression of EGFRvⅢ with ErbB-2 enhances tumorigenesis：EGFRvⅢ mediated constitutively activated and sustained signaling pathways，whereas EGF-induced a transient effect on EGFR-mediated signaling pathways［J］.Cancer Biol Ther，2008，7（11）：1818-1829.
|
| ［3］ |
Friedman HS，Bigner DD.Glioblastoma multiforme and the epidermal growth factor receptor［J］.N End J Med，2005，353（19）：1997-1999.
|
| ［4］ |
Patel D，Lahiji A，Patel S，et al.Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vⅢ on the cell surface［J］.Anticancer Res，2007，27（5）：3355-3366.
|
| ［5］ |
Li G，Wong AJ.EGF receptor variant Ⅲ as a target antigen for tumor immunotherapy［J］.Expert Rev Vaccines，2008，7（7）：977-985.
|
| ［6］ |
Stutz MA，Shattuck DL，Laederich MB，et al.LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRv Ⅲ［J］.Oncogene，2008，27（43）：5741-5752.
|
| ［7］ |
Li B，Yuan M，Kim IA，et al.Mutant epidermal growth factor receptor displays increased signaling through the phospha-tidylinostol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin［J］.Oncogene，2004，23（26）：4594-4602.
|
| ［8］ |
Theys J，Jutten B，Dubois L，et al.The deletion mutant EGFRvⅢsignificantly contributes to stress resistance typical for the tumor microenvironment［J］.Radiother Oncol，2009，92（3）：399-404.
|
| ［9］ |
Zhang Y，Su H，Rahimi M，et al.EGFRv Ⅲ-induced estrogenindependence，tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer［J］.Int J Cancer，2009，125（9）：2021-2028.
|
| ［10］ |
Luo X，Gong X，Tang K.Suppression of EGFRv Ⅲ-mediated proliferation and tumor genesis of breast cancer cells by ribozyme［J］.Int J Cancer，2003，104（6）：716-721.
|
| ［11］ |
Allen LF，Lenehan PF，Eiseman IA，et al.Potential benefits of the irreversible pan-erbB inhibitor，CI-1033，in the treatment of breast cancer［J］.Seminars in oncology，2002，29（3）：11-21.
|
| ［12］ |
Han W，Zhang T，Yu H，et al.Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvⅢ［J］.Cancer biol ther，2006，5（10）：1361-1368.
|
| ［13］ |
Gong J，Nikrui N，Chen D，et al.Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity［J］.Immunology，2000，165（3）：1705-1711.
|
| ［14］ |
Wu AH，Xiao J，Anker L，et al.Identification of EGFRvⅢ-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas［J］.J Neurooncol，2006，76（1）：23-30.
|
| ［15］ |
Heimberger AB，Crotty LE，Archer GE，et al.Epidermal growth factor receptor V Ⅲ peptide vaccination is efficacious against established intracerebral tumors［J］.Clin Cancer Res，2003，9（11）：4247-4254.
|
| ［16］ |
Schmittling RJ，Archer GE，Mitchell DA，et al.Detection of humoral response in patients with glioblastoma receiving EGFRvⅢ-KLH vaccines［J］.J Immunol Methods，2008，339（1）：74-81.
|
| ［17］ |
Wikstrand CJ，Cole VR，Crotty LE，et al.Generation of antiidiotypic reagents in the EGFRv Ⅲtumor-associated antigen system［J］.Cancer Immunol Immunother，2002，50（12）：639-652.
|
| ［18］ |
Wang X，Ko EC，Peng L，et al.Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23：enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2［J］.Cancer Res，2005，65（15）：6976-6983.
|
| ［19］ |
Modjtahedi H，Moscatello DK，Box G，et al.Targeting of cells expressing wild-type EGFR and type-Ⅲ mutant EGFR（EGFRvⅢ）by anti-EGFR MAb ICR62：a two-pronged attack for tumor therapy［J］.IntJ Cancer，2003，105（2）：273-280.
|
| ［20］ |
Modjtahedi H，Moscatello DK，Box G，et al.Targeting of cells expressing wild-type EGFR and type-Ⅲmutant EGFR（EGFRvⅢ）by anti-EGFR MAb ICR62：a two-pronged attack for tumor therapy［J］.Int J Cancer，2003，105（2）：273-280.
|
| ［21］ |
Perera RM，Narita Y，Furnari FB，et al.Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity［J］.Clin Cancer Res，2005，11（17）：6390-6399.
|
| ［22］ |
Patel D，Lahiji A，Patel S，et al.Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vⅢ on the cell surface［J］.Anticancer Res，2007，27（5）：3355-3366.
|
| ［23］ |
Denholt CL，Hansen PR，Pedersen N，et al.Identification of novel peptide ligands for the cancer-specific receptor mutation EGFRvⅢusing a mixture-based synthetic combinatorial library［J］.Biopolymers，2009，91（3）：201-206.
|
| ［24］ |
Balyasnikova Ⅳ，Franco Gou R，Mathis JM，et al.Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvⅢ on the cell surface［J］.J Tissue Eng Regen Med，2010，4（4）：247-258.
|
| ［25］ |
Scott AM，Lee FT，Tebbutt N，et al.A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors［J］.Proc NatlAcad Sci USA，2007，104（10）：4071-4076.
|
| ［26］ |
Fury MG，Lipton A，Smith KM，et al.A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocytecolony stimulating factor in patients with advanced solid tumors［J］.Cancer Immunol Immunother，2008，57（2）：155-163.
|
| ［27］ |
Ou C，Wu FX，Luo Y，et al.Expression and significance of epidermal growth factor receptor variant type Ⅲ in hepatocellular carcinoma［J］.Ai Zheng，2005，24（2）：166-169.
|
| ［28］ |
Bonner JA，Harari PM，Giralt J，et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck［J］.N EnglJ Med，2006，354（6）：567-578.
|
| ［29］ |
Van Cutsem E，Peeters M，Siena S，et al.Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer［J］.J Clin Oncol，2007，25（13）：1658-1664.
|
| ［30］ |
Food KA，Yang XD，Weiner LM，et al.Preclinical and clinical evaluations of ABX-EGF，a fully human anti-epidermal growth factor receptor antibody［J］.Int J Radiat Oncol Biol Phys，2004，58（3）：984-990.
|
| ［31］ |
RochaLima CM，Soares HP，Raez LE，et al.EGFR targeting of solid tumors［J］.Cancer Control，2007，14（3）：295-304.
|
| ［32］ |
Overman MJ，Hoff PM.EGFR-targeting therapies in colorectal cancer［J］.Dis Colon Rectum，2007，50（8）：1259-1270.
|
| ［33］ |
Gupta P，Han SY，Hoqado Madruqa M，et al.Development of an EGFRvⅢ specific recombinant antibody［J］.BMC Biotecthnol，2010，10：72.
|